David Westberg - Nanexa AB Chief Officer
| NANEXA Stock | 1.27 0.05 3.79% |
Insider
David Westberg is Chief Officer of Nanexa AB
| Age | 63 |
| Phone | 46 18 10 03 00 |
| Web | https://www.nanexa.com |
Nanexa AB Management Efficiency
The company has return on total asset (ROA) of (0.1972) % which means that it has lost $0.1972 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3902) %, meaning that it generated substantial loss on money invested by shareholders. Nanexa AB's management efficiency ratios could be used to measure how well Nanexa AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| MD MBA | Mendus AB | 60 | |
| Johan MD | Lidds AB | 69 | |
| Jenni Bjornulfson | Lidds AB | 52 | |
| Lotta Ferm | Mendus AB | 57 | |
| Pr Tufveson | Corline Biomedical AB | N/A | |
| Marc Willuhn | Klaria Pharma Holding | 54 | |
| PerOlof Gunnesson | Mendus AB | 78 | |
| Fredrik Hubinette | Klaria Pharma Holding | 54 | |
| Hakan Skogstrom | Alzinova AB | 62 | |
| Annette Moldrup | Lidds AB | 62 | |
| Kristina Torfgard | Alzinova AB | N/A | |
| Kia Bengtsson | Lidds AB | 54 | |
| Jeroen MD | Mendus AB | 52 | |
| Alex MD | Mendus AB | 73 | |
| Hans MD | Klaria Pharma Holding | 65 | |
| Erik Manting | Mendus AB | 52 | |
| Jesper Wiklund | Klaria Pharma Holding | 54 | |
| Leopold Bertea | Mendus AB | 58 | |
| Matthew Lindon | Lidds AB | 50 | |
| Anders Sandberg | Alzinova AB | 51 | |
| Henrik Nittmar | Corline Biomedical AB | 57 | |
Management Performance
| Return On Equity | -0.39 | |||
| Return On Asset | -0.2 |
Nanexa AB Leadership Team
Elected by the shareholders, the Nanexa AB's board of directors comprises two types of representatives: Nanexa AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nanexa. The board's role is to monitor Nanexa AB's management team and ensure that shareholders' interests are well served. Nanexa AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nanexa AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Otto MSc, Director Director | ||
| Marten Rooth, Head CoFounder | ||
| David Westberg, Chief Officer | ||
| Anders Johansson, CoFounder Property | ||
| Mikael Asp, Head Expert | ||
| Bengt MSc, Medical Director | ||
| Joel Hellrup, Head RD | ||
| Bjrn Svanstrm, Chief Officer |
Nanexa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nanexa AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.39 | |||
| Return On Asset | -0.2 | |||
| Profit Margin | (2.23) % | |||
| Operating Margin | (2.00) % | |||
| Current Valuation | 34.48 M | |||
| Shares Outstanding | 60.7 M | |||
| Shares Owned By Insiders | 40.75 % | |||
| Price To Book | 0.68 X | |||
| Price To Sales | 3.34 X | |||
| Revenue | 2.37 M |
Thematic Opportunities
Explore Investment Opportunities
Other Information on Investing in Nanexa Stock
Nanexa AB financial ratios help investors to determine whether Nanexa Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Nanexa with respect to the benefits of owning Nanexa AB security.